Literature DB >> 17170617

Update on beta-blockers in hypertension.

Debbie L Cohen1, Raymond R Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17170617      PMCID： PMC8109740          DOI： 10.1111/j.1524-6175.2006.05178.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  7 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

Review 2.  Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Authors:  Lars Hjalmar Lindholm; Bo Carlberg; Ola Samuelsson
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Atenolol and cardiovascular risk: an issue close to the heart.

Authors:  Ian B Wilkinson; Carmel M McEniery; John R Cockcroft
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

6.  Roundtable discussion: the role of Beta blockers in the management of hypertension.

Authors:  Marvin Moser; Thomas G Pickering; Wiliam C Cushman
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-05       Impact factor: 3.738

Review 7.  Nitric oxide mechanisms in the pathogenesis of global risk.

Authors:  R Preston Mason
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.